Dario selected to provide integrated approach
to improve employee cardiometabolic health - including support for
those taking a GLP-1 medication - musculoskeletal and behavioral
health
NEW
YORK, April 2, 2024 /PRNewswire/
-- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the
"Company"), a leader in the global digital health market, announced
today two new contracts to provide integrated chronic condition
management solutions for two national employers beginning in the
second quarter of 2024.
The first employer, a global private investment group, selected
Dario's cardiometabolic suite to help improve outcomes for
employees with cardiometabolic health conditions, including
diabetes, pre-diabetes, hypertension and weight management needs,
including support for individuals taking a GLP-1.
The second employer, a national professional services company,
selected Dario's full suite of solutions to deliver personalized
support for employees living with cardiometabolic health conditions
and commonly co-occurring musculoskeletal and behavioral health
needs.
Dario combines intelligent technologies with billions of data
insights gathered from a decade of consumer engagement to deliver
highly personalized experiences that keep members engaged over time
for optimal results. Employees enrolled in Dario's cardiometabolic
solution who are taking a GLP-1 medication will also have access to
a tailored experience to support long-term behavior change.
"The need for an integrated approach to address the most common
and chronic health needs continues to drive demand for Dario's
multi-chronic solutions. Our ability to ensure each employee
receives proven, highly personalized support – especially with the
growing use of GLP-1s – is the reason we believe that more
companies like our two new employer clients are selecting Dario and
we are excited to deliver the high-value support they require,"
said Rick Anderson, President of
Dario.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the expected timing of the launch of the solutions,
the benefits that may be realized by members using Dario's
solutions and the belief that its ability to ensure each employee
receives proven, highly personalized support is the reason it
believes that more companies are selecting Dario. Without
limiting the generality of the foregoing, words such as "plan,"
"project," "potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat
Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/two-national-employers-select-darios-integrated-chronic-condition-solution-to-improve-employee-health-302105644.html
SOURCE DarioHealth Corp.
